A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-525127-27-00

Enrollment

Registered

2026-05-15

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Myasthenia Gravis

Brief summary

Phase 1: Incidence of treatment-emergent adverse events; Phase 2: Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score

Detailed description

Aritinercept serum concentrations over time, Change from baseline in serum levels of IgG, IgM and IgA, Incidence of aritinercept anti-drug antibodies

Interventions

DRUGIsotone Natriumchloridlösung 0

DRUG9 % Braun Injektionslösung

DRUGAUR200

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Phase 1: Incidence of treatment-emergent adverse events; Phase 2: Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score	—

Secondary

Measure	Time frame
Aritinercept serum concentrations over time, Change from baseline in serum levels of IgG, IgM and IgA, Incidence of aritinercept anti-drug antibodies	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 16, 2026